Invention Grant
- Patent Title: Derivatives of erlotinib
- Patent Title (中): 厄洛替尼的衍生物
-
Application No.: US13176000Application Date: 2011-07-05
-
Publication No.: US08575339B2Publication Date: 2013-11-05
- Inventor: Xueheng Cheng
- Applicant: Xueheng Cheng
- Agent Justin Lampel
- Main IPC: C07D239/70
- IPC: C07D239/70

Abstract:
This invention relates to novel compounds and hydrochloric acid salts thereof. More specifically, this invention relates to novel compounds and hydrochloric acid salts thereof derived from erlotinib. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an epidermal growth factor receptor tyrosine kinase (EGFR) inhibitor, such as erlotinib.
Public/Granted literature
- US20130012528A1 NOVEL DERIVATIVES OF ERLOTINIB Public/Granted day:2013-01-10
Information query